Akira Yoshizaki
Iwate Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Akira Yoshizaki.
International Journal of Gynecological Cancer | 2011
Tadahiro Shoji; Eriko Takatori; Hideo Omi; Seisuke Kumagai; Akira Yoshizaki; Yoshihito Yokoyama; Hideki Mizunuma; Toshio Fujimoto; Tadao Takano; Nobuo Yaegashi; Toru Tase; Kenji Nakahara; Hirohisa Kurachi; Hiroshi Nishiyama; Toru Sugiyama
Objective: To evaluate the efficacy and safety of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of patients with recurrent ovarian cancer after previous treatment with platinum and taxane agents. Patients and Methods: A total of 42 patients with recurrent ovarian cancer who had an evaluable lesion and provided informed consent for participation in the present study were analyzed. Irinotecan was administered intravenously at a dose of 60 mg/m2 on days 1 and 15. Etoposide was administered orally at a daily dose of 50 mg/body weight from days 1 to 21. A 28-day period comprised one cycle. The tumor response, adverse events, progression-free survival, and overall survival were examined. Tumor response was evaluated based on the Response Evaluation Criteria in Solid Tumors and the serum CA125 levels (Gynecologic Cancer Intergroup criteria). Adverse events were assessed according to the NCI-CTCAE (version 3.0). Results: Partial response was observed in 21 patients, stable disease in 14 patients, and progressive disease in 7 patients. The response rate was 50.0%, and the clinical benefit (partial response + stable disease) rate was 83.3%. Hematological toxicities of at least grade 3 severity included leukopenia in 21 patients (50.0%), neutropenia in 22 patients (52.4%), thrombocytopenia in 1 patient (2.4%), anemia in 9 patients (21.4%), and febrile neutropenia in 3 patients (7.1%). Nonhematological toxicities of at least grade 3 severity included queasy feeling in 5 patients (11.9%), vomiting in 3 patients (7.1%), and diarrhea in 2 patients (4.8%). Acute myeloid leukemia occurred in one patient (2.4%). Conclusions: It is suggested that combination chemotherapy with irinotecan plus oral etoposide offers significant clinical benefit to patients with recurrent ovarian cancer previously treated with platinum and taxane agents.
Gynecologic and Obstetric Investigation | 2012
Tadahiro Shoji; Eriko Takatori; Rie Oyama; Seisuke Kumagai; Akimune Fukushima; Akira Yoshizaki; Toru Sugiyama
The name ‘tako-tsubo’ cardiomyopathy was initially used to describe a unique ‘short-neck round-flask’-shaped form of left ventricular apical ballooning, resembling a Japanese tako-tsubo, a jar (tsubo) used for capturing octopus (tako). Tako-tsubo cardiomyopathy exhibits acute onset, transient left ventricular apical wall motion abnormalities with chest symptoms and minimal myocardial enzymatic release, mimicking acute myocardial infarction in patients without angiographic stenosis on coronary angiography. There have been few case reports on tako-tsubo cardiomyopathy, and this disorder is especially rare in pregnant women. A 30-year-old woman who was pregnant with triplets, and had been treated with ritodrine hydrochloride for 12 weeks for threatened premature delivery, underwent cesarean section with spinal anesthesia at 30 weeks’ gestation. Three hours later, she complained of acute chest pain, dyspnea and episodes of unconsciousness. She was transferred to the intensive care unit and intubated for ventilatory support. We diagnosed heart failure due to tako-tsubo cardiomyopathy based on heart ultrasonography, blood tests, chest X-ray, electrocardiogram and myocardial scintigraphy. She was extubated from the ventilator after 3 days of catecholamine, furosemide and carperitide administration. She was discharged from the hospital on day 53 without symptoms.
Journal of Obstetrics and Gynaecology Research | 2012
Eriko Takatori; Tadahiro Shoji; Jiyu Miura; Satoshi Takeuchi; Akira Yoshizaki; Toru Sugiyama
Ovarian carcinoid is a rare tumor accounting for approximately 0.1% of all ovarian malignancies. We describe a case of peptide‐YY‐producing strumal carcinoid of the ovary associated with severe constipation. A 48‐year‐old woman was found to have a pelvic mass on ultrasonography when she visited her primary doctor for a health check‐up. She was thus referred to our department. Magnetic resonance imaging revealed a solid right ovarian tumor 60 × 50 mm in size. The patient underwent a right adnexectomy and was histopathologically diagnosed as having strumal carcinoid of the ovary. On immunohistochemical examination, the tumor cells were positive for peptide YY. The patients constipation resolved rapidly after surgery. Based on her clinical course, her constipation was considered to have been caused by the strumal carcinoid of the ovary. The clinical course of this case supports the previously recognized correlation between peptide‐YY‐producing ovarian carcinoid and constipation.
Archive | 2012
Tadahiro Shoji; Eriko Takatori; Hideo Omi; Masahiro Kagabu; Tastuya Honda; Yuichi Morohara; Seisuke Kumagai; Fumiharu Miura; Satoshi Takeuchi; Akira Yoshizaki; Toru Sugiyama
The methods used for treating stage Ib2-IIb cervical cancers, with a bulky mass, differ between Japan and Western countries. In Western countries, concurrent chemoradiation (CCRT) has been recommended as a standard therapy for such tumors based on the results of multiple large-scale randomized trials and meta-analyses (Morris et al., 1999; Rose et al., 1999; Whitney et al., 1999; Pearcey et al., 2002; Eifel et al. 2004; Green et al. 2001; Lukka et al., 2002). In Japan, Korea, Italy and some other countries, the neoadjuvant chemotherapy (NAC) approach has been extensively introduced to clinical practice (Sugiyama et al., 1999). NAC is considered to be clinically significant in 2 respects: it is expected to improve the radicality and safety of surgery by reducing tumor size; and it is expected to exert systemic effects, i.e., effects on lymph node occult micrometastases, etc. A disadvantage of NAC is delayed initiation of the primary treatment, suggesting the necessity of completing NAC as an auxiliary therapy within a short period of time. Therefore, we may find that NAC is valuable if it can exert efficacy rapidly with high platinum dose intensity (DI), assuring that subsequent primary surgical therapy can be performed as soon as possible. At our facility, a platinum-based regimen has been used for NAC in patients with cervical cancer. Herein, we review the efficacy and safety data on NAC for squamous cell carcinoma of the uterine cervix. We previously reported our interim data and now present the results of an ongoing pilot study on the efficacy and safety of NAC for non-squamous cell carcinoma of the uterine cervix.
Cancer Investigation | 2014
Tadahiro Shoji; Eriko Takatori; Satoshi Takeuchi; Akira Yoshizaki; Noriyuki Uesugi; Tamotsu Sugai; Toru Sugiyama
Forty-one patients diagnosed with atypical glangular cells (AGC) underwent surgery, and the histopathological diagnosis results for the resected specimens and the clinical features were analyzed. Out of 41 patients, final pathological diagnosis was endometrial cancer in 13 patients, cervical adenocarcinoma in 8, AIS in 7, CIN3 in 6, others in 2, and no lesions in 5. In comparison with previous reports, malignant or premalignant lesions were detected more frequently in patients with AGC who underwent surgery. We believe that conization or hysterectomy aimed at diagnosis and treatment, as well as endometrial histodiagnosis, should be carried out aggressively in patients with AGC.
Journal of Obstetrics and Gynaecology Research | 2013
Eriko Takatori; Tadahiro Shoji; Yuki Miura; Satoshi Takeuchi; Akira Yoshizaki; Toru Sugiyama
There have been no case reports of the risk of serious adverse events associated with the administration of irinotecan hydrochloride (CPT‐11) in patients with gynecologic cancer who are compound heterozygous for UGT1A1*6 and UGT1A1*28. A 71‐year‐old patient presented with recurrent stage IIIb cervical cancer. Combined chemotherapy was initiated with CPT‐11 (60 mg/m2 on days 1 and 8) plus nedaplatin (NDP; 80 mg/m2 on day 1), with each cycle lasting for 28 days. The patient was a compound heterozygote for UGT1A1*6 and UGT1A1*28. Hematotoxic adverse events observed during the chemotherapy were grade 4 neutropenia, grade 3 anemia, and grade 4 thrombocytopenia, and the non‐hematotoxic adverse events were grade 3 diarrhea and grade 3 fatigue. The findings in this patient indicate that CPT‐11 should be administered with great care, even at a dose of 60 mg/m2, in patients receiving combined therapy with CPT‐11 and NDP who are compound heterozygous for UGT1A1*6 and UGT1A1*28.
International Journal of Gynecological Cancer | 2007
Muneaki Shimada; Junzo Kigawa; Naoki Terakawa; Akira Yoshizaki; Tadahiro Shoji; Mitsuaki Suzuki; M. Hatae; Hitoshi Tsuda; M. Ohwada; Toru Sugiyama
Doxorubicin, platinum compounds, and taxanes represent the chemotherapeutic agents with the greatest activity in endometrial cancer. We conducted an optimal-dose determination of combination chemotherapy consisting of paclitaxel (TXL), doxorubicin, and carboplatin (CBDCA) (TAC) in patients with endometrial cancer. Patients with epithelial endometrial cancer requiring adjuvant therapy were enrolled between June 2003 and March 2005. No patients had received prior radiotherapy, and only two patients had previously undergone chemotherapy. Doxorubicin was infused on day 1, and TXL followed by CBDCA was administered on day 2. The starting dose was doxorubicin 35 mg/m2, TXL 120 mg/m2, and CBDCA area under the curve (AUC). The dose of each agent was gradually escalated. Patients were scheduled to receive at least four cycles of therapy. If patients experienced grade 4 neutropenia or neutropenic fever with grade 3 neutropenia, they were permitted to be administered granulocyte colony–stimulating factor after the second course. Twenty-seven patients were enrolled. Although four patients out of 27 experienced dose-limiting toxicities, a maximum tolerated dose was not established at the final dose level. Five patients (three for recurrent and two for advanced) had measurable lesions. There were four responders (three for partial response and one for complete response) in our series. The recommended dose of TAC therapy for endometrial cancer was doxorubicin 45 mg/m2 for day 1, TXL 150 mg/m2 and CBDCA AUC 5 for day 2.
International Journal of Gynecological Cancer | 2008
Masashi Takano; Toru Sugiyama; Nobuo Yaegashi; Michiko Sakuma; Mitsuaki Suzuki; Y. Saga; Kazuo Kuzuya; Junzo Kigawa; Muneaki Shimada; Hitoshi Tsuda; Takuya Moriya; Akira Yoshizaki; Tsunekazu Kita; Yoshihiro Kikuchi
Experimental and Therapeutic Medicine | 2012
Hiroi Kaku; Seisuke Kumagai; Hiroki Onoue; Anna Takada; Tadahiro Shoji; Fumiharu Miura; Akira Yoshizaki; Shinya Sato; Junzo Kigawa; Tsutomu Arai; Shinpei Tsunoda; Eiichiro Tominaga; Daisuke Aoki; Toru Sugiyama
Gynecologic Oncology | 2007
Shin Nishio; Toru Sugiyama; Tadahiro Shouji; Akira Yoshizaki; Ryo Kitagawa; Kimio Ushijima; Toshiharu Kamura